AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Citius Oncology shares surge 15.15% intraday after partnering with Verix AI and McKesson to boost LYMPHIR's CTCL rollout.
ByAinvest
Monday, Nov 24, 2025 9:41 am ET1min read
Citius Oncology (CTOR) surged 15.15% intraday trading after announcing a partnership with Verix AI to accelerate the commercial rollout of LYMPHIR for CTCL, alongside a distribution services agreement with McKesson for LYMPHIR. The collaboration with Verix AI highlights the company’s focus on leveraging artificial intelligence to enhance drug commercialization, while the McKesson deal strengthens LYMPHIR’s market accessibility. These developments, combined with a recent price target increase, signal growing confidence in the drug’s market potential and operational scalability, directly aligning with the stock’s sharp intraday rally.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet